![]() Results being presented at ESMO include an exploratory analysis of the efficacy and safety outcomes at five years of follow-up and additional analyses in patients who completed 35 cycles (approximately two years) of treatment with KEYTRUDA. KEYNOTE-189 (, NCT02578680) is a pivotal Phase 3, randomized trial evaluating KEYTRUDA plus pemetrexed and cisplatin or carboplatin for the first-line treatment of patients with metastatic nonsquamous NSCLC with no EGFR or ALK genomic tumor aberrations versus pemetrexed and platinum chemotherapy alone. Five-year OS data from KEYNOTE-042, which evaluated KEYTRUDA monotherapy versus platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC whose tumors expressed PD-L1 (TPS ≥1%), were presented at SITC 2021.Īs announced, data spanning more than 16 different types of cancer are being presented from Merck’s broad oncology portfolio and investigational pipeline at ESMO Congress 2022.įive-year data from an exploratory analysis of KEYNOTE-189 in metastatic nonsquamous NSCLC (abstract #973MO) Five-year OS data from KEYNOTE-024, which evaluated KEYTRUDA monotherapy versus chemotherapy for the first-line treatment of patients with metastatic NSCLC whose tumors expressed PD-L1 (tumor proportion score ≥50%), were presented at ESMO 2020. Results from KEYNOTE-189 (abstract #973MO) and KEYNOTE-407 (abstract #974MO) are being presented during a mini oral session at the European Society for Medical Oncology (ESMO) Congress 2022. “These results show meaningful improvements in five-year survival for patients receiving KEYTRUDA plus chemotherapy and reinforce the important role of these KEYTRUDA-based regimens as standards of care for metastatic non-small cell lung cancer.” Garassino, professor of medicine, University of Chicago, Hematology/Oncology, and principal investigator for KEYNOTE-189. “Prior to these landmark studies, lung cancer had a 10% five-year survival rate, one of the lowest of any cancer,” said Dr. In fact, in both studies, of the approximately 55 patients who completed two years of treatment, about 70% were alive at five years.” “Now, with more than five years of follow-up, these studies continue to show impressive survival outcomes and durable responses for patients receiving KEYTRUDA in combination with chemotherapy. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. “The overall survival findings from KEYNOTE-189 and KEYNOTE-407 changed the way patients with metastatic non-small cell lung cancer were treated and established KEYTRUDA plus chemotherapy as a foundational first-line treatment for this devastating disease,” said Dr. In addition to NSCLC, five-year survival data for KEYTRUDA have been presented in three other types of cancer, including bladder cancer (KEYNOTE-045), head and neck cancer (KEYNOTE-048) and melanoma (KEYNOTE-054). KEYTRUDA is the first immunotherapy to demonstrate a sustained five-year survival benefit both in combination with chemotherapy and as monotherapy for the first-line treatment of NSCLC. The median OS was 17.2 months for the KEYTRUDA plus chemotherapy group versus 11.6 months for the chemotherapy group. KEYTRUDA plus carboplatin-paclitaxel or nab-paclitaxel reduced the risk of death by 29% (HR=0.71 ) versus chemotherapy alone. At five years, KEYTRUDA plus pemetrexed and cisplatin or carboplatin more than doubled the median OS compared to chemotherapy alone (22.0 months versus 10.6 months) įor patients with metastatic squamous NSCLC, results from KEYNOTE-407 showed the five-year OS rate for KEYTRUDA plus carboplatin-paclitaxel or nab-paclitaxel was 18.4% versus 9.7% for chemotherapy alone. ![]() The KEYTRUDA-pemetrexed-platinum chemotherapy combination reduced the risk of death by 40% (HR=0.60 ). ![]() Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA, Merck’s anti-PD-1 therapy, plus chemotherapy continued to demonstrate a survival benefit and durable responses in two five-year exploratory analyses of pivotal Phase 3 studies as first-line treatment for metastatic non-small cell lung cancer (NSCLC):įor patients with metastatic nonsquamous NSCLC, data from KEYNOTE-189 demonstrated KEYTRUDA plus pemetrexed (ALIMTA ®) and platinum chemotherapy (cisplatin or carboplatin) had a five-year overall survival (OS) rate of 19.4% versus 11.3% for chemotherapy alone. In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials Five-year overall survival rate of 19.4% and 18.4% for KEYTRUDA plus chemotherapy in KEYNOTE-189 and KEYNOTE-407, respectively
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |